Skip to main content
Beximco Pharmaceuticals Ltd. logo

Beximco Pharmaceuticals Ltd. — Investor Relations & Filings

Ticker · BXP ISIN · US0885792061 LEI · 213800IMBBD6TIOQGB56 IL Manufacturing
Open in API
Filings indexed 125 across all filing types
Latest filing 2020-08-28 Regulatory Filings
Country BD Bangladesh
Listing IL BXP

About Beximco Pharmaceuticals Ltd.

https://www.beximcopharma.com

Beximco Pharmaceuticals Ltd. is a manufacturer of generic drugs and active pharmaceutical ingredients (APIs). The company produces a broad portfolio of over 500 products across various therapeutic categories, with a focus on providing access to affordable medicines. It has established a strong market differentiation through a range of high-tech, specialized products, including metered-dose and dry powder inhalers. Serving numerous emerging and developed markets globally, its manufacturing facilities are accredited by major international regulatory authorities, including those of the USA, European Union, Australia, and Canada.

Recent filings

Filing Released Lang Actions
Price Monitoring Extension
Regulatory Filings Classification · 1% confidence The document is a short, automated notification from the London Stock Exchange's Regulatory News Service (RNS) regarding a 'Price Monitoring Extension' for a specific security. It does not contain financial statements, management reports, or corporate governance disclosures. As it is a standard regulatory notification regarding trading parameters that does not fit into specific categories like M&A or dividends, it falls under the RNS (Regulatory Filings) category.
2020-08-28 English
Beximco and SII to cooperate on a COVID-19 vaccine
Regulatory Filings Classification · 1% confidence The document is a press release distributed via the London Stock Exchange's RNS (Regulatory News Service) regarding a business partnership between Beximco Pharmaceuticals and the Serum Institute of India for COVID-19 vaccine distribution. As it is a general corporate announcement regarding business operations and strategic partnerships that does not fit into specific categories like M&A, financial results, or governance, it is classified as a Regulatory Filing (RNS).
2020-08-28 English
Board Change
Board/Management Information Classification · 1% confidence The document is an official announcement from Beximco Pharmaceuticals Ltd regarding the appointment of a new Independent Non-Executive Director, Professor Mamtaz Uddin Ahmed. The text explicitly states 'Board Change' as the subject and provides details about the appointee's background and directorships. This fits the definition of a Board/Management Information filing.
2020-07-30 English
Q3 Financial Results and Business Update
Interim / Quarterly Report Classification · 1% confidence The document is a quarterly financial report for Beximco Pharmaceuticals Ltd, covering the third quarter and nine months ended 31 March 2020. It includes detailed consolidated financial statements (Statement of Financial Position and Statement of Profit or Loss) and business updates. While it is distributed via an RNS (Regulatory News Service) header, the content is a comprehensive interim financial report containing substantive financial data, which qualifies it as an Interim/Quarterly Report (IR) rather than a simple announcement. 9M 2020
2020-06-23 English
World’s first generic remdesivir for COVID-19
Regulatory Filings Classification · 1% confidence The document is an RNS (Regulatory News Service) announcement from the London Stock Exchange regarding Beximco Pharmaceuticals Ltd. It details the launch of a new generic drug (remdesivir) for COVID-19 treatment. Since it is a general corporate announcement regarding business operations and product launches that does not fit into specific categories like financial reports, dividends, or director dealings, it falls under the RNS (Regulatory Filings) category.
2020-05-21 English
COVID-19 Update
Regulatory Filings Classification · 1% confidence The document is an RNS (Regulatory News Service) announcement from the London Stock Exchange regarding Beximco Pharmaceuticals Ltd. It provides a business update concerning the impact of COVID-19 on operations, supply chain, and financial outlook. It does not constitute a full financial report, but rather a corporate update/announcement. Given the 'RNS' header and the nature of the content as a general regulatory announcement, it falls under the RNS category.
2020-05-04 English

Browse filings by year

8 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.